The Atorvastatin API Market Size was valued at USD 1.5 Billion in 2022. The Atorvastatin API market industry is projected to grow from USD 1.61 Billion in 2023 to USD 2.87 Billion by 2032.
The Atorvastatin API market is witnessing significant growth, driven by the increasing prevalence of cardiovascular diseases and the rising demand for lipid-lowering agents. Atorvastatin, a key player in this market, is renowned for its efficacy in reducing cholesterol levels and preventing cardiovascular events. This pharmaceutical ingredient belongs to the statin class of drugs, which are widely used as cholesterol-lowering agents.
Cholesterol API is a critical component of the Atorvastatin market, as it addresses the escalating global health concern of elevated cholesterol levels. High cholesterol is a major risk factor for heart disease and strokes, making lipid-lowering agents like Atorvastatin indispensable in managing and preventing these conditions. As a result, pharmaceutical companies are focusing on the development and production of Atorvastatin API to meet the growing demand for cholesterol-lowering medications.
Lipid-lowering agent, another key LSI keyword, emphasizes the broader category of drugs to which Atorvastatin belongs. These agents play a crucial role in managing dyslipidemia, a condition characterized by abnormal levels of lipids in the blood. Atorvastatin, with its potent cholesterol-lowering properties, is at the forefront of lipid-lowering therapies.
The Atorvastatin API market is driven not only by its effectiveness but also by the increasing awareness of cardiovascular health and preventive medicine. Governments and healthcare organizations globally are actively promoting initiatives to educate the public about the importance of managing cholesterol levels. This heightened awareness contributes to the growing demand for Atorvastatin API as a vital component in lipid-lowering formulations.
Segment Analysis
The atorvastatin API industry has been studied extensively by MRFR experts, with respect to applications.
The key applications covered in the market report are hypertriglyceridemia, dyslipidemia, hypercholesterolemia, and more. Out of these, the hypercholesterolemia category can take the lead in the global market and touch a valuation of USD 210,753.23 thousand by 2023-end, estimates MRFR. Hypercholesterolemia cases across the globe have doubled in recent years, given the increasing adoption of lifestyle choices like bad eating habits, tobacco consumption and lack of exercise, all of which increase the cholesterol level in the blood. Some other secondary factors giving rise to these cases can be dialysis, alcohol intake, diabetes mellitus (Type 2), monoclonal gammopathy, obesity, and more.
Major Key Players:
The global Atorvastatin API Companies are Teva Pharmaceutical Industries Ltd (Israel), Jubilant Life Sciences Ltd (India), Dr. Reddy’s Laboratories Ltd (India), Sun Pharmaceutical Industries Ltd (India), Ind-Swift Labs Ltd (India), Morepen Laboratories Ltd (India), Zhejiang Hisun Pharmaceutical Co Ltd (China), Anuh Pharma Ltd (India), Centrient Pharmaceuticals (The Netherlands) and Cadila Pharmaceuticals (India)
Recent Developements
Feb 2023 Jubilant Bhartia Group, a player in the life sciences industry, plans to build a cutting-edge laboratory at Hyderabad's Genome Valley to take advantage of the talent pool there. Hari S. Bhartia, the founder and co-chairman of Jubilant Bhartia Group, announced that Jubilant Biosys will shortly open a facility in Genome Valley. Nevertheless, neither Bhartia nor the government disclosed the project's investment amounts. Jubilant's arrival in Hyderabad is evidence of the city's dynamic ecosystem, infrastructure, and talent pool that foster innovation. With Jubilant's entrance, Hyderabad will be home to all significant CROs in India.
Oct 2023 Sun Pharmaceutical Industries Ltd. has signed agreements to purchase minority holdings in Ezerx Health Tech Ltd. & Agatsa Software Ltd. From their prior agreement to buy 26.09% of Agatsa Software, Sun Pharma boosted its shareholding by 4.04%. Following this transaction, the pharmaceutical corporation will hold 30.13% of the startup manufacturer of digital diagnostic gadgets. By October 2023 and December 2023, the purchase of interests in Ezerx Health Tech and Agatsa Software is anticipated to be finished. While Agatsa Software is an early-stage digital diagnostic device startup, Ezerx Health Tech manufactures, markets, and sells non-invasive diagnostic and auxiliary medical equipment. The pharmaceutical company has stated that it wants to devote 7-8% of its sales in the current fiscal to R&D efforts to expand its line of goods across therapeutic categories. For FY24, it anticipates consolidated topline growth in the upper single digits.
Regional Analysis
In 2017, with the biggest share of 40.64%, North America secured the lead in the global market and is projected to record a CAGR of 3.10% during the conjectured period. Alarming surge in heart diseases in conjunction with bad eating habits and rise in obesity are major reasons behind the market lucrativeness in the region. Technological innovations in drugs along with the expanding supply channel networks of leading firms in the region also adds to the projected growth.
The European industry is presumed to cross USD 131,094.04 thousand by the year, thanks to the massive prevalence of hypercholesterolemia as well as mixed dyslipidemia. France, followed by the UK, is the biggest gainer in the regional market, as a majority of the pharmaceutical companies in the country are striving to expedite their research and development to produce huge volumes of drugs.
Browse Related Reports:
Lung cancer therapeutics Market
Vacuum blood collection tube Market
For More Information, Please Visit @ Market Research Future
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek